These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 15644478)

  • 1. Are incentive-based formularies inversely associated with drug utilization in managed care?
    Gleason PP; Gunderson BW; Gericke KR
    Ann Pharmacother; 2005 Feb; 39(2):339-45. PubMed ID: 15644478
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of incentive-based formularies on prescription-drug utilization and spending.
    Huskamp HA; Deverka PA; Epstein AM; Epstein RS; McGuigan KA; Frank RG
    N Engl J Med; 2003 Dec; 349(23):2224-32. PubMed ID: 14657430
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of 3-tier formularies on drug treatment of attention-deficit/hyperactivity disorder in children.
    Huskamp HA; Deverka PA; Epstein AM; Epstein RS; McGuigan KA; Muriel AC; Frank RG
    Arch Gen Psychiatry; 2005 Apr; 62(4):435-41. PubMed ID: 15809411
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Incentive formularies and changes in prescription drug spending.
    Landon BE; Rosenthal MB; Normand SL; Spettell C; Lessler A; Underwood HR; Newhouse JP
    Am J Manag Care; 2007 Jun; 13(6 Pt 2):360-9. PubMed ID: 17567237
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of a three-tier formulary on antidepressant utilization and expenditures.
    Hodgkin D; Parks Thomas C; Simoni-Wastila L; Ritter GA; Lee S
    J Ment Health Policy Econ; 2008 Jun; 11(2):67-77. PubMed ID: 18509214
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Budget impact of tegaserod on a managed care organization formulary.
    Bloom MA; Barghout V; Kahler KH; Bentkover J; Kurth H; Gralnek IM; Spiegel BM
    Am J Manag Care; 2005 Apr; 11(1 Suppl):S27-34. PubMed ID: 15926761
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Consumer response to dual incentives under multitiered prescription drug formularies.
    Gilman BH; Kautter J
    Am J Manag Care; 2007 Jun; 13(6 Pt 2):353-9. PubMed ID: 17567236
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Consumer attitudes and factors related to prescription switching decisions in multitier copayment drug benefit plans.
    Ganther-Urmie JM; Nair KV; Valuck R; McCollum M; Lewis SJ; Turpin RS
    Am J Manag Care; 2004 Mar; 10(3):201-8. PubMed ID: 15032257
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of a copay increase on pharmaceutical utilization, expenditures, and treatment continuation.
    Motheral BR; Henderson R
    Am J Manag Care; 1999 Nov; 5(11):1383-94. PubMed ID: 10662412
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of 3-tier pharmacy benefit design and increased consumer cost-sharing on drug utilization.
    Landsman PB; Yu W; Liu X; Teutsch SM; Berger ML
    Am J Manag Care; 2005 Oct; 11(10):621-8. PubMed ID: 16232003
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Managing drug costs: the perception of managed care pharmacy directors.
    Litton LM; Sisk FA; Akins ME
    Am J Manag Care; 2000 Jul; 6(7):805-14. PubMed ID: 11067377
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A benefit-based copay for prescription drugs: patient contribution based on total benefits, not drug acquisition cost.
    Fendrick AM; Smith DG; Chernew ME; Shah SN
    Am J Manag Care; 2001 Sep; 7(9):861-7. PubMed ID: 11570020
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Formulary: what it is and how it works.
    Smith G
    J Healthc Resour Manag; 1996 Sep; 14(7):11-3. PubMed ID: 10161584
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Incorporating quality of life data into managed care formulary decisions: a case study with salmeterol.
    Bukstein DA
    Am J Manag Care; 1997 Nov; 3(11):1701-6. PubMed ID: 10178468
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A comparison of mail-service and retail community pharmacy claims in 5 prescription benefit plans.
    Clark BE; Siracuse MV; Garis RI
    Res Social Adm Pharm; 2009 Jun; 5(2):133-42. PubMed ID: 19524861
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A bitter pill: formulary variability and the challenge to prescribing physicians.
    Shrank WH; Ettner SL; Glassman P; Asch SM
    J Am Board Fam Pract; 2004; 17(6):401-7. PubMed ID: 15575031
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of a retrospective drug utilization review on potentially inappropriate prescribing in the elderly.
    Starner CI; Norman SA; Reynolds RG; Gleason PP
    Am J Geriatr Pharmacother; 2009 Feb; 7(1):11-9. PubMed ID: 19281936
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of 2 employer-sponsored population health management programs on medical care cost and utilization.
    Mattke S; Serxner SA; Zakowski SL; Jain AK; Gold DB
    Am J Manag Care; 2009 Feb; 15(2):113-20. PubMed ID: 19284808
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Do drug formulary policies reflect evidence of value?
    Neumann PJ; Lin PJ; Greenberg D; Berger M; Teutsch S; Mansley E; Weinstein MC; Rosen AB
    Am J Manag Care; 2006 Jan; 12(1):30-6. PubMed ID: 16402886
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Retrospective, long-term follow-up study of the effect of a three-tier prescription drug copayment system on pharmaceutical and other medical utilization and costs.
    Fairman KA; Motheral BR; Henderson RR
    Clin Ther; 2003 Dec; 25(12):3147-61; discussion 3144-6. PubMed ID: 14749153
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.